Publications by authors named "Jolanta Siller Matula"
According to the ESC guidelines, cangrelor may be considered in P2Y12-inhibitor-naïve acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). The aim of this review is to summarize available evidence on the optimal maintenance therapy with P2Y12 receptor inhibitor after cangrelor. Transitioning from cangrelor to a thienopyridine, but not ticagrelor, can be associated with a drug-drug interaction (DDI); therefore, a ticagrelor loading dose (LD) can be given any time before, during, or at the end of a cangrelor infusion, while a LD of clopidogrel or prasugrel should be administered at the time the infusion of cangrelor ends or within 30 minutes before the end of infusion in the case of a LD of prasugrel.
View Article and Find Full Text PDFDe-escalation of dual antiplatelet (DAPT) intensity may be considered in patients with high risk of bleeding after acute coronary syndrome. Some high risk patients after de-escalation may require antithrombotic therapy prolonged over 12 months. With the current guideline recommended strategies, there are some doubts and uncertainties with respect to the transition period.
View Article and Find Full Text PDFCurrent evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y inhibitor is essential for the prevention of thrombotic events after percutaneous coronary interventions. However, dual antiplatelet therapy is associated with increased bleeding which may outweigh the benefits. This has set the foundations for customizing antiplatelet treatments to the individual patient.
View Article and Find Full Text PDFSodium-glucose cotransporter 2 (SGLT2, SLC5A2) is a promising target for a new class of drug primarily established as kidney-targeting as well as emerging class of glucose-lowering drugs in diabetes. Studies showed that SGLT2 inhibitors also have a systemic impact via indirectly targeting the heart and kidneys which exerts broad cardio- and nephroprotective effects. Additionally, as cancer cells tightly require glucose supply, studies also questioned how SGLT2 inhibitors impact molecular pathology and cellular metabolism in cancer hallmarks.
View Article and Find Full Text PDFBackground: Empagliflozin administered after acute myocardial infarction proofed to improve cardiometabolic parameters and biomarkers, but the impact on cardiac function is still largely unknown. The aim of this post-hoc echocardiographic sub-analysis of the EMMY trial was to provide in-depth echocardiographic analysis on the effects of empagliflozin versus placebo on standard and novel echocardiographic structural and functional parameters after acute myocardial infarction.
Methods: In this post-hoc analysis of the EMMY trial a subset of 313 patients (157 empagliflozin vs.
Article Synopsis
- Leaflet thrombosis (LT) is a complex and poorly understood complication that can occur after transcatheter aortic valve implantation (TAVI), prompting the need for better prediction models to identify at-risk patients.
- A study involving 101 TAVI patients utilized imaging and lab tests to determine various clinical and biological factors associated with LT, discovering that certain elevated and decreased lab values could predict its occurrence.
- The researchers created an EFFORT score to quantify the risk, finding that patients scoring 2 or higher had an 85.7% likelihood of developing LT, indicating the score's potential as a powerful tool for risk assessment post-TAVI.
Background: Managing patients with atrial fibrillation (AF) and worsening renal function (WRF) remains a clinical challenge due to the need of dose adjustment of non-vitamin K antagonist oral anticoagulants.
Objectives: To determine the incidence of WRF in patients with AF treated with edoxaban, the association of WRF with clinical outcomes, and predictors of WRF and clinical outcomes in these patients.
Methods: This is a subanalysis of the Edoxaban Treatment in routiNe clinical prActice for patients with non-valvular Atrial Fibrillation in Europe study (NCT02944019), an observational study of edoxaban-treated patients with AF.
Article Synopsis
- ACE2 is the main receptor for SARS-CoV-2, and this study investigates the role of specific miRNAs (miR-10b-5p, miR-124-3p, miR-200b-3p, miR-26b-5p, miR-302c-5p) in predicting COVID-19 patient outcomes and their impact on the cardiovascular system.
- The researchers measured miRNA expression in 79 hospitalized COVID-19 patients and 32 healthy volunteers at three different time points, finding that lower levels of miR-200b-3p could indicate longer hospital stays and higher mortality risk.
- The study found distinct expression patterns of miRNAs in COVID-19
Background: Out-of-hospital cardiac arrest (OHCA) complicated by refractory ventricular fibrillation (VF) is associated with poor outcome. Beta-1-receptor selective blockade might overcome refractory VF and improve survival. This trial investigates the efficacy and safety of prehospital landiolol in OHCA and refractory VF.
View Article and Find Full Text PDFBackground: Platelet P2Y12 antagonist ticagrelor reduces cardiovascular mortality after acute myocardial infarction (AMI) compared to clopidogrel, but the underlying mechanism is unknown. Because activated platelets release proatherogenic and proinflammatory microRNAs, including miR-125a, miR-125b and miR-223, we hypothesized that the expression of these miRNAs is lower on ticagrelor, compared to clopidogrel.
Objectives: We compared miR-125a, miR-125b and miR-223 expression in plasma of patients after AMI treated with ticagrelor or clopidogrel.
Aims: The long-term outcomes of out of hospital cardiac arrest (OHCA) survivors are not well known.
Methods And Results: Using the Myocardial Ischaemia National Audit Project (MINAP) registry, linked to Office for National Statistics mortality data, we analysed 661 326 England, Wales, and Northern Ireland acute myocardial infarction (AMI) patients; 14 127 (2%) suffered OHCA and survived beyond 30 days of hospitalization. Patients dying within 30 days of admission were excluded.
Article Synopsis
- - The study reviewed cases of myocarditis linked to COVID-19 vaccination, analyzing data from the EudraVigilance database and published literature for characteristics like age, gender, vaccine type, and doses.
- - A total of 16,514 cases of myocarditis or pericarditis were reported, primarily in males aged 18-64, with a low mortality rate of 2 cases per 10 million doses administered.
- - Overall findings indicated that myocarditis is a rare but serious side effect of COVID-19 vaccines, particularly mRNA types, but can have a good prognosis with timely recognition and treatment.
Background: Transcatheter aortic valve replacement (TAVR) showed safety and efficacy in patients with severe aortic stenosis. Commissural alignment (CA) during TAVR has the potential to reduce the impact of the prostheses on accessibility of coronary arteries, as misalignment of the neocommissures could cause partial overlap with coronary ostia. Therefore, the aim of this study was to investigate the impact of CA on coronary overlap rates.
View Article and Find Full Text PDFTiming of SGLT2i initiation after acute myocardial infarction.
Cardiovasc Diabetol
September 2023
Background: Pharmacological post-MI treatment is routinely initiated at intensive/cardiac care units. However, solid evidence for an early start of these therapies is only available for dual platelet therapy and statins, whereas data on beta blockers and RAAS inhibitors are heterogenous and mainly limited to STEMI and heart failure patients. Recently, the EMMY trial provided the first evidence on the beneficial effects of SGLT2 inhibitors (SGLT2i) when initiated early after PCI.
View Article and Find Full Text PDFArticle Synopsis
- Heart failure (HF) is linked to higher risks of major bleeding and all-cause death among atrial fibrillation (AF) patients on non-vitamin K antagonist oral anticoagulants (NOACs), particularly with lower left ventricular ejection fraction (LVEF).
- In a study of over 13,000 AF patients treated with edoxaban, 14.1% had HF, and those with HF experienced greater rates of strokes, major bleeding, and mortality compared to those without HF.
- The findings suggest a need for improved management strategies for AF patients with HF, even though NOACs effectively reduced ischaemic event risks regardless of HF status.
Article Synopsis
- - Conventional dual antiplatelet therapy (DAPT) involves the use of aspirin and a potent P2Y inhibitor (prasugrel or ticagrelor) for 12 months in patients with acute coronary syndromes, which lowers ischaemic risk but raises the likelihood of bleeding.
- - Strategies to minimize bleeding include de-escalating DAPT intensity (switching to a less potent P2Y inhibitor or lower doses) or shortening the duration of therapy, both of which need careful risk assessment for each patient.
- - The Consensus Statement summarizes existing evidence for these strategies, highlights the importance of assessing ischaemic and bleeding risks, and offers expert guidance to help clinicians customize DAPT approaches for better patient outcomes.
: Patients with prediabetes are at increased risk of coronary artery disease (CAD). However, the association between prediabetes and adverse clinical outcomes following percutaneous coronary intervention (PCI) is inconsistent, in contrast to outcomes in patients with diabetes mellitus (DM). Thus, this meta-analysis evaluated the impact of dysglycaemia on PCI outcomes.
View Article and Find Full Text PDFObjective: Women have a higher comorbidity burden and a lower survival rate after acute myocardial infarction (AMI) than men. This analysis aimed to investigate the impact of sex on the effect of treatment with the sodium glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin immediately after an AMI.
Methods: Participants were randomized to either empagliflozin or placebo and followed for 26 weeks after initiating the treatment no later than 72 hours after a percutaneous coronary intervention following an AMI.
Background: Type ll myocardial infarction (T2MI) is caused by a mismatch between myocardial oxygen supply and demand. One subset of individuals is T2MI caused by acute hemorrhage. Traditional MI treatments including antiplatelets, anticoagulants, and revascularization can worsen bleeding.
View Article and Find Full Text PDF: MicroRNAs (miRNA, miR) are small, non-coding RNAs which have become increasingly relevant as diagnostic and prognostic biomarkers. The objective of this study was the investigation of blood-derived miRNAs and their link to long-term all-cause mortality in patients who suffered from non-ST-segment elevation acute coronary syndrome (NSTE-ACS). : This study was an observational prospective study, which included 109 patients with NSTE-ACS.
View Article and Find Full Text PDFEndovascular thrombectomy with or without intravenous thrombolysis in large-vessel ischemic stroke: A non-inferiority meta-analysis of 6 randomised controlled trials.
Vascul Pharmacol
June 2023
Article Synopsis
- This study investigates whether thrombectomy alone is as effective as combining it with intravenous thrombolysis for patients with acute ischemic stroke caused by large-vessel blockage.
- A meta-analysis of six trials involving 2,334 patients showed that functional independence at 90 days was similar between the two treatments, with slight variations in success and risk of hemorrhage.
- While thrombectomy alone proved to be non-inferior at a wider margin, there might still be important differences in outcomes that need further exploration.
Article Synopsis
- The study examined sex differences in patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusion (CTO), finding that female patients were older and had higher rates of diabetes and hypertension.
- Male patients had more complex procedures and used advanced techniques more frequently than female patients.
- Despite women experiencing a higher risk of procedural complications, their rates of in-patient mortality and major adverse cardiovascular events were similar to those of men.
Article Synopsis
- TAVI is a treatment for aortic stenosis in high-risk patients, but many patients still experience major complications after the procedure.
- This study focused on how TAVI affects the levels of certain microRNAs related to platelet function and whether these levels can predict complications.
- Results showed that levels of miR-223 increased after TAVI, and lower baseline levels of miR-223 were linked to higher risk of complications, although it wasn't statistically significant when considering other factors.